Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Recruiting
Phase 2
Phase 3
Interventional Study
Glaucoma
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 2/3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 610 (estimated)
- Sponsor
- Glaukos Corporation · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Diagnosis of open-angle glaucoma or ocular hypertension in the study eye
Exclusion Criteria:
* Prior incisional glaucoma surgery in the study eye
* Prior argon laser trabeculoplasty (ALT) in the study eye
* Prior minimally invasive glaucoma (MIGS) surgery in the study eye
Contacts